Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
21
AXIM Quote, Financials, Valuation and Earnings
Last price:
$0.0100
Seasonality move
:
5.9%
Day range:
$0.0094 - $0.0152
52-week range:
$0.0016 - $0.0288
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
127.90x
P/B ratio:
--
Volume:
1.5M
Avg. volume:
495.1K
1-year change:
543.89%
Market cap:
$5.8M
Revenue:
$70.5K
EPS (TTM):
-$0.02
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, AXIM Biotechnologies, Inc. has -- downside to fair value with a price target of -- per share.
AXIM vs. S&P 500
-
Over the past 5 trading days, AXIM Biotechnologies, Inc. has underperformed the S&P 500 by -30.71% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
AXIM Biotechnologies, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
AXIM Biotechnologies, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter AXIM Biotechnologies, Inc. reported revenues of $17.5K.
Earnings Growth
-
AXIM Biotechnologies, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter AXIM Biotechnologies, Inc. reported earnings per share of -$0.00.
Enterprise value:
11.2M
EV / Invested capital:
--
Price / LTM sales:
127.90x
EV / EBIT:
--
EV / Revenue:
524.03x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-9.77x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-103.02%
Net Income Margin (TTM):
-4452.06%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-3257.86%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Income Statement | ||||||
| Revenue | $26.2K | $92.9K | -- | $17.5K | -- | |
| Gross Profit | -$400.9K | -$338.5K | -$438.1K | -$92.4K | -$108.1K | |
| Operating Income | -$3.9M | -$2.3M | -$1.4M | -$569.4K | -$290.4K | |
| EBITDA | -$3.4M | -$1.9M | -$918.7K | -$461.3K | -$182.3K | |
| Diluted EPS | -$0.05 | -$0.02 | -$0.00 | -$0.01 | $0.00 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $411.8K | $173.2K | $97.5K | $20.2K | $2.8K | |
| Total Assets | $10.7M | $4.6M | $4.2M | $3.7M | $3.2M | |
| Current Liabilities | $1.4M | $2.7M | $8.4M | $6.6M | $6.2M | |
| Total Liabilities | $9.3M | $8.3M | $14M | $13.3M | $13.7M | |
| Total Equity | $1.4M | -$3.6M | -$9.7M | -$9.5M | -$10.4M | |
| Total Debt | $5.7M | $5M | $5.5M | $6.3M | $7.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$1.5M | -$759K | -$1.1M | -$261.5K | -$673.6K | |
| Cash From Investing | -$2.7K | -$2.8K | -- | -- | -- | |
| Cash From Financing | $1.5M | $670.4K | $1.1M | $170.9K | $669.2K | |
| Free Cash Flow | -$1.5M | -$761.7K | -$1.1M | -$261.5K | -$673.6K | |
AXIM
Sector
Market Cap
$5.8M
$28.1M
Price % of 52-Week High
60.4%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-21.32%
-1.49%
1-Year Price Total Return
543.89%
-17.13%
Beta (5-Year)
-0.613
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.0161
200-day SMA
Buy
Level
$0.0075
Bollinger Bands (100)
Buy
Level
-0.0007 - 0.0193
Chaikin Money Flow
Buy
Level
27.8M
20-day SMA
Sell
Level
$0.0188
Relative Strength Index (RSI14)
Sell
Level
36.9340
ADX Line
Sell
Level
36.9203
Williams %R
Buy
Level
-88.4833
50-day SMA
Sell
Level
$0.0133
MACD (12, 26)
Buy
Level
0.0004
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Sell
Level
-24.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-34.7366)
Sell
CA Score
(Annual)
Level (-15.7628)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (670.1818)
Buy
Piotroski F Score
(Annual)
Level (5)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (0)
Revenue Forecast
Earnings per Share Forecast
Company Profile
AXIM Biotechnologies, Inc. operates as a biotechnology company, which engages in the development of diagnostic healthcare solutions. Its product categories include Eye Health, SARS-CoV-2, and fentanyl neutralizing antibody test. The company was founded on November 18, 2010 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, AXIM has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AXIM average analyst price target in the past 3 months is --.
-
Where Will AXIM Biotechnologies, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that AXIM Biotechnologies, Inc. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About AXIM Biotechnologies, Inc.?
Analysts are divided on their view about AXIM Biotechnologies, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that AXIM Biotechnologies, Inc. is a Sell and believe this share price will rise from its current level to --.
-
What Is AXIM Biotechnologies, Inc.'s Price Target?
The price target for AXIM Biotechnologies, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AXIM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for AXIM Biotechnologies, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of AXIM?
You can purchase shares of AXIM Biotechnologies, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase AXIM Biotechnologies, Inc. shares.
-
What Is The AXIM Biotechnologies, Inc. Share Price Today?
AXIM Biotechnologies, Inc. was last trading at $0.0100 per share. This represents the most recent stock quote for AXIM Biotechnologies, Inc.. Yesterday, AXIM Biotechnologies, Inc. closed at $0.0116 per share.
-
How To Buy AXIM Biotechnologies, Inc. Stock Online?
In order to purchase AXIM Biotechnologies, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get AXIM Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
AXIM
Sector
P/E ratio
--
23.89x
PEG ratio
--
-0.01x
P/B ratio
--
1.81x
Price / LTM sales
127.90x
1.59x
Growth Metrics
AXIM
Sector
Revenue growth
76.04%
4.62%
Earnings growth
--
11.06%
Revenue (5-year growth)
-27.38%
6.5%
Earnings forecast
--
-$0.21
Profitability
AXIM
Sector
Profitability FY 2024
-$369.3K
$3.6M
Return on invested capital
--
-31.84%
Return on assets
-103.02%
-27.96%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Nov
14
Next Earnings Date
Dec
25
Estimated Next Earnings Date
Mar
26
Balance Sheet
AXIM
Sector
Total cash
$7.2K
$26.4M
Short term investments
--
$25.7M
Total assets
$3.4M
$76.9M
Long term debt
$6.6M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
Sell
32
SMX alert for Dec 24
SMX (Security Matters) Plc [SMX] is down 8.94% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
